Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy

Inclusion Criteria: * Sign Informed Consent. * 21 years of age or older. * Able to follow instructions and willing to attend required study visits. * Clinical diagnosis of ocular hypertension, primary open-angle, or pigment dispersion glaucoma in at least one eye (qualifying eye). * Intra-ocular pressure (IOP) considered to be safe in both eyes in such a way that should assure clinical stability of vision and the optic nerve throughout the trial. * Must have best corrected visual acuity of 6/60 (6/60 Snellen, 1.0 LogMAR) or better in each eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Presence of other primary or secondary glaucomas not listed in inclusion criterion. * Presence of corneal dystrophies. * Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. * Intraocular conventional surgery or laser surgery in qualifying eye(s) less than three months prior to Visit 1. * Risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's best judgment. * Women of childbearing potential not using reliable means of birth control. * Women who are pregnant or lactating. * Participation in any other investigational study within 30 days prior to Visit 1. * Current or anticipated use of systemic corticosteroids, by any route except inhaled, for greater than two weeks during the trial. * Severe allergic rhinitis * History of ocular herpes simplex. * Other protocol-defined exclusion criteria may apply.